Pharma Capital

Akers Biosciences enjoys stellar second quarter with sales up 25% year-on-year

Revenues were US$1.2mln for the three-month period ended June 30, up around 25% on the same period last year and 1.8-times the turnover recorded in the first-quarter.
financial-report.jpg
The numbers are starting add up for Akers

Rapid diagnostics specialist Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) said quarterly sales were the strongest since the company’s admission to America’s NASDAQ market in 2014.

Revenues were US$1.2mln for the three-month period ended June 30, up around 25% on the same period last year and 1.8-times the turnover recorded in the first-quarter.

Sales were derived from all of its main markets – the US, China and the rest of the world – and spread across its main product lines, including its breakthrough rapid heparin allergy test.

The company has developed a range of breath-test diagnostics which monitor conditions such as oxidative stress, cholesterol levels and whether the body is burning fat.

View full AKR profile

Akers Biosciences, Inc. Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.